Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II single arm clinical trial to evaluate the efficacy and safety of the combination of Tarceva (erlotinib hydrochloride) and Rapamune (sirolimus) in the treatment of metastatic renal cell carcinoma

Next Previous
X
Search
Trial Profile

A phase II single arm clinical trial to evaluate the efficacy and safety of the combination of Tarceva (erlotinib hydrochloride) and Rapamune (sirolimus) in the treatment of metastatic renal cell carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erlotinib (Primary) ; Sirolimus
  • Indications Renal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Jan 2012 Planned end date changed from 1 May 2009 to 1 May 2012 as reported by ClinicalTrials.gov.
    • 01 Dec 2008 Planned end date changed from 1 May 2007 to 1 May 2009 as reported by ClinicalTrials.gov.
    • 01 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top